Plasma cell-free DNA quantification is highly correlated to tumor burden in children with neuroblastoma

DOI: 10.1002/cam4.1586
Cancer Medicine, 2018, 7, 3022.

#	Paper	IF	Citations
33	Plasma cell-free DNA quantification is highly correlated to tumor burden in children with neuroblastoma. *Cancer Medicine*, **2018**, 7, 3022	4.8	28
32	Opportunities and challenges of circulating biomarkers in neuroblastoma. *Open Biology*, **2019**, 9, 190056	7	14
31	The emerging role of cell-free DNA as a molecular marker for cancer management. *Biomolecular Detection and Quantification*, **2019**, 17, 100087	12	200
30	Dynamic alterations of plasma cell free DNA in response to chemotherapy in children with neuroblastoma. *Cancer Medicine*, **2019**, 8, 1558-1566	4.8	11
29	Chromosome band 11q23 deletion predicts poor prognosis in bone marrow metastatic neuroblastoma patients without MYCN amplification. *Cancer Communications*, **2019**, 39, 68	9.4	4
28	5-Hydroxymethylcytosine Profiles in Circulating Cell-Free DNA Associate with Disease Burden in Children with Neuroblastoma. *Clinical Cancer Research*, **2020**, 26, 1309-1317	12.9	11
27	Implementation of the plasma MYCN/NAGK ratio to detect MYCN amplification in patients with neuroblastoma. *Molecular Oncology*, **2020**, 14, 2884-2893	7.9	3
26	A Highly Sensitive Next-Generation Sequencing-Based Genotyping Platform for Mutations in Plasma from Non-Small Cell Lung Cancer Patients. *Cancers*, **2020**, 12,	6.6	1
25	Circulating tumor DNA in neuroblastoma. *Pediatric Blood and Cancer*, **2020**, 67, e28311	3	0
24	Evaluating the quantity, quality and size distribution of cell-free DNA by multiplex droplet digital PCR. *Scientific Reports*, **2020**, 10, 12564	4.9	24
23	Developing a Low-Cost, Simple-to-Use Electrochemical Sensor for the Detection of Circulating Tumour DNA in Human Fluids. *Biosensors*, **2020**, 10,	5.9	5
22	Long interspersed nuclear element 1 hypomethylation has novel prognostic value and potential utility in liquid biopsy for oral cavity cancer. *Biomarker Research*, **2020**, 8, 53	8	5
21	Different primers for diagnosing circulating cell-free DNA of colorectal cancer.. *Translational Cancer Research*, **2020**, 9, 3435-3442	0.3	1
20	Increased plasma concentration of cell-free DNA precedes disease recurrence in children with high-risk neuroblastoma. *BMC Cancer*, **2020**, 20, 102	4.8	9
19	Liquid biomarkers for the management of paediatric neuroblastoma: an approach to personalised and targeted cancer therapy. *Journal of Radiotherapy in Practice*, **2021**, 20, 217-229	0.4	
18	Optimisation of an Electrochemical DNA Sensor for Measuring KRAS G12D and G13D Point Mutations in Different Tumour Types. *Biosensors*, **2021**, 11,	5.9	1
17	Molecular Genetics in Neuroblastoma Prognosis. *Children*, **2021**, 8,	2.8	1

16	High-risk Neuroblastoma: Poor Outcomes Despite Aggressive Multimodal Therapy. *Current Cancer Therapy Reviews*, **2021**, 17,	0.4	
15	Association of the Neutrophil Extracellular Traps Formation With the Production of Circulating Cell-Free DNA and Anti-Cardiolipin Autoantibody in Patients With a Metastatic Colorectal Cancer. *SSRN Electronic Journal*,	1	0
14	Diagnostic accuracy of circulating-free DNA for the determination of MYCN amplification status in advanced-stage neuroblastoma: a systematic review and meta-analysis. *British Journal of Cancer*, **2020**, 122, 1077-1084	8.7	7
13	The expression of PHOX2B in bone marrow and peripheral blood predicts adverse clinical outcome in non-high-risk neuroblastoma. *Pediatric Hematology and Oncology*, **2021**, 1-14	1.7	1
12	Association of neutrophil extracellular traps with the production of circulating DNA in patients with colorectal cancer.. *IScience*, **2022**, 25, 103826	6.1	2
11	Is Tissue Still the Issue? The Promise of Liquid Biopsy in Uveal Melanoma.. *Biomedicines*, **2022**, 10,	4.8	1
10	Cell-Free DNA Variables including Gene Mutations in CA15-3 Normal Breast Cancer Reflect Prognosis.. *Disease Markers*, **2022**, 2022, 5470166	3.2	
9	Transcending Blood-Opportunities for Alternate Liquid Biopsies in Oncology.. *Cancers*, **2022**, 14,	6.6	0
8	Recent clinical research on the application of liquid biopsy in neuroblastoma.. *Chinese Journal of Contemporary Pediatrics*, **2022**, 24, 339-344	0.8	
7	Circulating Cell-Free DNA Assessment in Biofluids from Children with Neuroblastoma Demonstrates Feasibility and Potential for Minimally Invasive Molecular Diagnostics.. *Cancers*, **2022**, 14,	6.6	1
6	Circulating tumor cells in neuroblastoma: Current status and future perspectives. *Cancer Medicine*,	4.8	0
5	Advancing therapy for neuroblastoma. *Nature Reviews Clinical Oncology*,	19.4	3
4	The Utility of Repetitive Cell-Free DNA in Cancer Liquid Biopsies. *Diagnostics*, **2022**, 12, 1363	3.8	0
3	The Tumor and Its Microenvironment as Complementary Sources of Cancer Biomarkers. **2022**, 379-400		
2	Longitudinal evaluation of serum microRNAs as biomarkers for neuroblastoma burden and therapeutic p53 reactivation. **2023**, 5,		0
1	Diagnostic and prognostic value of plasma cell-free DNA combined with VEGF-C in laryngeal squamous cell carcinoma. **2023**, 67, 101895		0